Rare Diseases

Biography

Mr. Schliebner is a clinical strategist with a 25-year background in clinical drug development focused on rare diseases, orphan drugs, and advanced therapeutics. He develops innovative solutions and strategic considerations to help overcome the operational, logistical, and ethical challenges inherent to conducting research with rare disease patients. Mr. Schliebner’s efforts are focused on patient-centered approaches to drug development; reducing the burden of clinical trial participation; and leveraging novel and disruptive technologies to bring new therapies to patients faster. Committed to collaborative efforts to further drug development, Mr. Schliebner has developed active partnerships with rare disease patient-focused organizations, patient advocacy groups, drug development institutes, and academic research centers. He serves on leadership committees for a variety of rare disease societies and congresses, and also regularly speaks on novel strategies to accelerate rare disease drug development. Previously, Mr. Schliebner served as the Chief Operating Officer for an international cancer research institute focused on developing tumor-specific research consortia to accelerate the development of new targeted therapies. He holds a Master’s Degree in Public Health (MPH) from the University of Utah School of Medicine, and completed a Graduate Research Fellowship at The National Institutes of Health.

Research Interest

rare diseases, orphan drugs, and advanced therapeutics